Corruption risks in health procurement during the COVID-19 pandemic and anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks: a rapid review
- PMID: 38001483
- PMCID: PMC10675881
- DOI: 10.1186/s12992-023-00994-x
Corruption risks in health procurement during the COVID-19 pandemic and anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks: a rapid review
Abstract
Background: Health systems are often susceptible to corruption risks. Corruption within health systems has been found to negatively affect the efficacy, safety, and, significantly, equitable distribution of health products. Enforcing effective anti-corruption mechanisms is important to reduce the risks of corruption but requires first an understanding of the ways in which corruption manifests. When there are public health crises, such as the COVID-19 pandemic, corruption risks can increase due to the need for accelerated rates of resource deployment that may result in the bypassing of standard operating procedures.
Main body: A rapid review was conducted to examine factors that increased corruption risks during the COVID-19 pandemic as well as potential anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks. A search was conducted including terms related to corruption, COVID-19, and health systems from January 2020 until January 2022. In addition, relevant grey literature websites were hand searched for items. A single reviewer screened the search results removing those that did not meet the inclusion criteria. This reviewer then extracted data relevant to the research objectives from the included articles. 20 academic articles and 17 grey literature pieces were included in this review. Majority of the included articles described cases of substandard and falsified products. Several papers attributed shortages of these products as a major factor for the emergence of falsified versions. Majority of described corruption instances occurred in low- and middle-income countries. The main affected products identified were chloroquine tablets, personal protective equipment, COVID-19 vaccine, and diagnostic tests. Half of the articles were able to offer potential anti-corruption strategies.
Conclusion: Shortages of health products during the COVID-19 pandemic seemed to be associated with increased corruption risks. We found that low- and middle-income countries are particularly vulnerable to corruption during global emergencies. Lastly, there is a need for additional research on effective anti-corruption mechanisms.
Keywords: COVID- 19; Corruption; Falsified medicines; Global health; Substandard medicines.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Corruption risks in COVID-19 vaccine deployment: lessons learned for future pandemic preparedness.Global Health. 2025 Mar 7;21(1):8. doi: 10.1186/s12992-025-01096-6. Global Health. 2025. PMID: 40055685 Free PMC article.
-
An interdisciplinary review of digital technologies to facilitate anti-corruption, transparency and accountability in medicines procurement.Glob Health Action. 2020;13(sup1):1695241. doi: 10.1080/16549716.2019.1695241. Glob Health Action. 2020. PMID: 32194014 Free PMC article.
-
The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk.Glob Health Action. 2020;13(sup1):1694745. doi: 10.1080/16549716.2019.1694745. Glob Health Action. 2020. PMID: 32194011 Free PMC article. Review.
-
Anti-corruption in global health systems: using key informant interviews to explore anti-corruption, accountability and transparency in international health organisations.BMJ Open. 2022 Dec 22;12(12):e064137. doi: 10.1136/bmjopen-2022-064137. BMJ Open. 2022. PMID: 36549737 Free PMC article.
-
A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain.Expert Opin Drug Saf. 2022 Aug;21(8):1061-1088. doi: 10.1080/14740338.2022.2091543. Epub 2022 Jun 28. Expert Opin Drug Saf. 2022. PMID: 35714366
Cited by
-
Corruption risks in COVID-19 vaccine deployment: lessons learned for future pandemic preparedness.Global Health. 2025 Mar 7;21(1):8. doi: 10.1186/s12992-025-01096-6. Global Health. 2025. PMID: 40055685 Free PMC article.
-
COVID-19 ethics: unique aspects and a review as of early 2024.Monash Bioeth Rev. 2024 Jun;42(1):55-86. doi: 10.1007/s40592-024-00199-x. Epub 2024 Jul 13. Monash Bioeth Rev. 2024. PMID: 39003388 Free PMC article. Review.
-
Leveraging malaria vaccines and mRNA technology to tackle the global inequity in pharmaceutical research and production towards disease elimination.Malar J. 2024 May 6;23(1):136. doi: 10.1186/s12936-024-04972-5. Malar J. 2024. PMID: 38711053 Free PMC article. Review.
References
-
- World Health Organization. Who director-general's opening remarks at the media briefing on COVID-19–11 March 2020. 2020. https://www.who.int. Accessed 31 Mar 2022.
-
- Iyengar KP, Vaishya R, Bahl S, Vaish A. Impact of the coronavirus pandemic on the supply chain in healthcare. Br J Healthc Manage. 2020;26(6):1–4. doi: 10.12968/bjhc.2020.0047. - DOI
-
- World Health Organization. Shortage of personal protective equipment endangering health workers worldwide. 2020. https://www.who.int. Accessed 4 Aug 2022.
-
- Transparency International. Why fighting corruption matters in times of COVID-19. 2020. https://www.transparency.org. Accessed 18 Jan 2022.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical